Fig. 9: In vivo functional activity of scIgG-306C7B3 based on prolonged survival of AAV2-HBKO treated (Thy-1)-[A30P]-hα-synuclein mice. | npj Parkinson's Disease

Fig. 9: In vivo functional activity of scIgG-306C7B3 based on prolonged survival of AAV2-HBKO treated (Thy-1)-[A30P]-hα-synuclein mice.

From: AAV-mediated expression of a new conformational anti-aggregated α-synuclein antibody prolongs survival in a genetic model of α-synucleinopathies

Fig. 9

a Comparison of non-treated with control antibody treated (scIgG-anti-FITC) animals. No detrimental effect of the AAV-treatment could be observed (p = 0.47). b Low and mid doses of AAV2HBKO coding for scIgG-306C7B3 demonstrate delayed initial mortality but no overall increase in survival (p = 0.99 and 0.71, respectively). c Significant increased survival observed in high dose AAV2HBKO-scIgG-306C7B3 compared to control antibody treated animals (p = 0.03; comparison toward non-treated animals p = 0.09).

Back to article page